OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Show More...
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.84 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-09 2011-09 2012-09 2013-09 2014-09 2015-09 2016-09 2017-09 2018-09 2019-09 TTM Earnings Per Share USD -11.68 -28.21 -29.36 -14.4 -9.74 -1.98 -0.93 Dividends USD Payout Ratio % * Shares Mil 2.0 2.0 2.0 3.0 5.0 18.0 32.0 Book Value Per Share * USD 0.55 -9.29 -1.46 -0.23 -0.19 Free Cash Flow Per Share * USD -17.61 -9.01 -7.6 -2.73 Return on Assets % -59.01 -227.4 -357.78 -180.14 -223.25 -182.86 -334.81 Financial Leverage (Average) Return on Equity % Return on Invested Capital % Interest Coverage -13.75 -20.27 -35.26 -5.82 -7.67 -9.94 -14.57 Current Ratio 0.41 0.16 0.28 0.14 0.1 0.67 0.4 Quick Ratio 0.36 0.12 0.12 0.11 0.05 0.4 0.2 Debt/Equity